Boutique Venture Partners

Delfina is a company that specializes in developing a personalized prenatal care system aimed at ensuring the safety of mothers and infants during pregnancy. By leveraging data and machine learning, Delfina's platform creates individualized pregnancy care plans that assess patient risk through various metrics. This approach not only enhances interventional workflows but also improves provider efficiency, facilitating early intervention in prenatal care. Delfina's commitment to data-driven insights is paving the way for clinical innovation, ultimately striving to deliver equitable and cost-effective healthcare solutions for expectant families.

Operator of a SaaS-based healthcare price transparency platform intended to aggregate and contextualize price transparency, insurance, and demographic data. The company's platform offers health plans a simple way to comply with the CMS (Centers for Medicare and Medicaid Services) price transparency legislation while digitizing how patients shop, book, and pay for healthcare, enabling users to realize average cost savings to guide every healthcare purchasing decision.

Surge is a biotechnology company dedicated to enhancing surgical outcomes for patients. It has developed an advanced immunological model known as Surge2surgery, which predicts postoperative infections. This innovative platform integrates a single-cell analysis of the immune system conducted prior to surgery with clinical data, utilizing a proprietary machine-learning algorithm. By examining millions of immune cells from a small blood sample, Surge's technology simulates surgical trauma in a controlled environment, allowing for improved predictions and potentially better patient care.

FluidAI Medical is a company dedicated to enhancing patient care through innovative technology in post-operative recovery. It has developed a smart catheter system that employs artificial intelligence to monitor patients' health data within the body. This proactive approach enables the early detection of postoperative complications, allowing healthcare providers to access critical health information promptly. By leveraging data-driven insights, FluidAI aims to improve recovery outcomes and transform the standards of post-operative care.

Smartlens is a clinical-stage Med Tech company focused on developing innovative technologies for diagnosing and treating glaucoma, a leading cause of irreversible blindness. Its primary product, miLens, is a microfluidic-based smart contact lens designed for continuous monitoring of intraocular pressure (IOP), addressing the urgent need for home-based monitoring solutions. Current clinical trials indicate that miLens offers an accurate alternative to traditional office-based devices, potentially enhancing early diagnosis and personalized treatment for patients. The technology is non-invasive and utilizes a unique electronics-free sensor, which is supported by a robust portfolio of patents across multiple countries. In addition to its core focus on glaucoma, Smartlens is exploring applications for its technology in monitoring intracranial pressure, associated with neurological disorders and cancers, in collaboration with Stanford University Labs. The company has been recognized for its innovative contributions to medical technology and has gained visibility through various media outlets and industry conferences. Smartlens aims to improve patient outcomes, reduce treatment costs, and mitigate the societal impact of blindness through its cutting-edge solutions.

Zeda, formerly known as PrinterPrezz and Vertex Manufacturing, is a technology solutions company based in Fremont, California. Established in 2017, Zeda specializes in advanced manufacturing technologies, particularly in the fields of additive manufacturing, nanotechnology, and precision manufacturing. The company develops and manufactures innovative medical devices, such as the GAIA™ Lumbar Interbody Fusion Device, and provides essential tools including 3D printing machines, manipulation software, and scanners. Zeda serves highly regulated industries, including medical, aerospace, space, and defense, with a mission to enhance lives through the integration of groundbreaking technologies and innovative ideas. Its commitment to fostering collaboration and incubating new concepts positions Zeda as a leader in its sector.

Zeda, formerly known as PrinterPrezz and Vertex Manufacturing, is a technology solutions company based in Fremont, California. Established in 2017, Zeda specializes in advanced manufacturing technologies, particularly in the fields of additive manufacturing, nanotechnology, and precision manufacturing. The company develops and manufactures innovative medical devices, such as the GAIA™ Lumbar Interbody Fusion Device, and provides essential tools including 3D printing machines, manipulation software, and scanners. Zeda serves highly regulated industries, including medical, aerospace, space, and defense, with a mission to enhance lives through the integration of groundbreaking technologies and innovative ideas. Its commitment to fostering collaboration and incubating new concepts positions Zeda as a leader in its sector.

Surge is a biotechnology company dedicated to enhancing surgical outcomes for patients. It has developed an advanced immunological model known as Surge2surgery, which predicts postoperative infections. This innovative platform integrates a single-cell analysis of the immune system conducted prior to surgery with clinical data, utilizing a proprietary machine-learning algorithm. By examining millions of immune cells from a small blood sample, Surge's technology simulates surgical trauma in a controlled environment, allowing for improved predictions and potentially better patient care.

Delfina is a company that specializes in developing a personalized prenatal care system aimed at ensuring the safety of mothers and infants during pregnancy. By leveraging data and machine learning, Delfina's platform creates individualized pregnancy care plans that assess patient risk through various metrics. This approach not only enhances interventional workflows but also improves provider efficiency, facilitating early intervention in prenatal care. Delfina's commitment to data-driven insights is paving the way for clinical innovation, ultimately striving to deliver equitable and cost-effective healthcare solutions for expectant families.

CuraFi is a healthcare delivery and management company that specializes in providing specialty infusion services for patients with complex medical conditions. The company offers an integrated specialty pharmacy and care delivery payment platform aimed at enhancing affordability and access to specialty medications. By aligning physicians and payors, CuraFi's platform facilitates the management of patient costs, reduces medication expenses, and enables predictable, sustainable payments on a per member per month basis. This approach not only improves continuity of care but also allows independent healthcare providers to generate new revenue streams while delivering cost-effective treatment and access to essential medications for their patients.

FluidAI Medical is a company dedicated to enhancing patient care through innovative technology in post-operative recovery. It has developed a smart catheter system that employs artificial intelligence to monitor patients' health data within the body. This proactive approach enables the early detection of postoperative complications, allowing healthcare providers to access critical health information promptly. By leveraging data-driven insights, FluidAI aims to improve recovery outcomes and transform the standards of post-operative care.

Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.

miRecule, Inc. is a biotechnology company based in Gaithersburg, Maryland, established in 2016. The company specializes in developing a microRNA-based drug discovery platform, DREAmiR, aimed at addressing challenges in cancer therapy and muscular dystrophy. This innovative platform leverages genomic and outcome data from thousands of patients to identify genetic abnormalities associated with diseases. miRecule formulates RNA therapeutics that can directly target and correct these genetic issues. The platform integrates genomic sequencing, expression, and prognostic data from numerous cancer patients with high throughput screening of microRNA candidates for replacement therapy. miRecule is focused on creating highly tailored therapeutics, with lead programs targeting Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy, ultimately striving to improve the quality of life for patients suffering from debilitating conditions.

Docbot, Inc. is an artificial intelligence technology company based in Irvine, California, that specializes in gastrointestinal diseases. The company develops web-based applications for iOS and Android devices, offering a clinical decision support system that aggregates patient information and provides cloud analytics for healthcare professionals. Its flagship product is built on the UltivisionAI software platform, which focuses on real-time image analysis and automated reporting. This platform is designed to detect colorectal cancer and other gastrointestinal conditions by integrating various data sources from imaging systems and pathology requisitions. Docbot aims to enhance patient care and streamline clinical workflows, ultimately reducing cancer risks and improving outcomes for patients in the gastrointestinal specialty.

FluidAI Medical is a company dedicated to enhancing patient care through innovative technology in post-operative recovery. It has developed a smart catheter system that employs artificial intelligence to monitor patients' health data within the body. This proactive approach enables the early detection of postoperative complications, allowing healthcare providers to access critical health information promptly. By leveraging data-driven insights, FluidAI aims to improve recovery outcomes and transform the standards of post-operative care.

Mesentech Inc. is a regenerative medicine company based in Vancouver, Canada, specializing in the development of therapeutics that target bone-related diseases. The company utilizes a unique prodrug platform that delivers bi-specific small-molecule therapeutics selectively to bone tissue, minimizing side effects associated with systemic exposure. Its lead product, MES1007, is a bone-targeted prodrug of a prostaglandin mimetic, designed to potentially reverse bone loss linked to conditions such as Duchenne muscular dystrophy and osteoporosis. Mesentech's proprietary technology overcomes the challenges of delivering medications to the difficult-to-treat bone environment, which often requires high drug doses and can lead to significant side effects. Through pre-clinical in-vivo models, the effectiveness of this bone-targeting system has been confirmed, positioning Mesentech to address various low-bone-density disorders and enhance bone healing outcomes. The company was incorporated in 2013 and continues to innovate in the field of bone therapeutics.

Zeda, formerly known as PrinterPrezz and Vertex Manufacturing, is a technology solutions company based in Fremont, California. Established in 2017, Zeda specializes in advanced manufacturing technologies, particularly in the fields of additive manufacturing, nanotechnology, and precision manufacturing. The company develops and manufactures innovative medical devices, such as the GAIA™ Lumbar Interbody Fusion Device, and provides essential tools including 3D printing machines, manipulation software, and scanners. Zeda serves highly regulated industries, including medical, aerospace, space, and defense, with a mission to enhance lives through the integration of groundbreaking technologies and innovative ideas. Its commitment to fostering collaboration and incubating new concepts positions Zeda as a leader in its sector.

Docbot, Inc. is an artificial intelligence technology company based in Irvine, California, that specializes in gastrointestinal diseases. The company develops web-based applications for iOS and Android devices, offering a clinical decision support system that aggregates patient information and provides cloud analytics for healthcare professionals. Its flagship product is built on the UltivisionAI software platform, which focuses on real-time image analysis and automated reporting. This platform is designed to detect colorectal cancer and other gastrointestinal conditions by integrating various data sources from imaging systems and pathology requisitions. Docbot aims to enhance patient care and streamline clinical workflows, ultimately reducing cancer risks and improving outcomes for patients in the gastrointestinal specialty.

miRecule, Inc. is a biotechnology company based in Gaithersburg, Maryland, established in 2016. The company specializes in developing a microRNA-based drug discovery platform, DREAmiR, aimed at addressing challenges in cancer therapy and muscular dystrophy. This innovative platform leverages genomic and outcome data from thousands of patients to identify genetic abnormalities associated with diseases. miRecule formulates RNA therapeutics that can directly target and correct these genetic issues. The platform integrates genomic sequencing, expression, and prognostic data from numerous cancer patients with high throughput screening of microRNA candidates for replacement therapy. miRecule is focused on creating highly tailored therapeutics, with lead programs targeting Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy, ultimately striving to improve the quality of life for patients suffering from debilitating conditions.

QMENTA is a software platform focused on imaging-based clinical studies, primarily aimed at enhancing the diagnosis and treatment of brain diseases. The company offers a cloud-based data management engine that integrates patented, AI-powered analytical algorithms alongside a marketplace of partnered algorithms. This platform allows healthcare professionals to compliantly collect, process, and analyze large-scale brain images and associated data efficiently. QMENTA's solutions encompass data management systems, clinical trials, neuroimaging disease packages, and neuro-data services, thereby facilitating improved medical imaging management and supporting clinical care and neuro research.

Smartlens is a clinical-stage Med Tech company focused on developing innovative technologies for diagnosing and treating glaucoma, a leading cause of irreversible blindness. Its primary product, miLens, is a microfluidic-based smart contact lens designed for continuous monitoring of intraocular pressure (IOP), addressing the urgent need for home-based monitoring solutions. Current clinical trials indicate that miLens offers an accurate alternative to traditional office-based devices, potentially enhancing early diagnosis and personalized treatment for patients. The technology is non-invasive and utilizes a unique electronics-free sensor, which is supported by a robust portfolio of patents across multiple countries. In addition to its core focus on glaucoma, Smartlens is exploring applications for its technology in monitoring intracranial pressure, associated with neurological disorders and cancers, in collaboration with Stanford University Labs. The company has been recognized for its innovative contributions to medical technology and has gained visibility through various media outlets and industry conferences. Smartlens aims to improve patient outcomes, reduce treatment costs, and mitigate the societal impact of blindness through its cutting-edge solutions.

Zeda, formerly known as PrinterPrezz and Vertex Manufacturing, is a technology solutions company based in Fremont, California. Established in 2017, Zeda specializes in advanced manufacturing technologies, particularly in the fields of additive manufacturing, nanotechnology, and precision manufacturing. The company develops and manufactures innovative medical devices, such as the GAIA™ Lumbar Interbody Fusion Device, and provides essential tools including 3D printing machines, manipulation software, and scanners. Zeda serves highly regulated industries, including medical, aerospace, space, and defense, with a mission to enhance lives through the integration of groundbreaking technologies and innovative ideas. Its commitment to fostering collaboration and incubating new concepts positions Zeda as a leader in its sector.

Frontier Bio Corporation, based in Oakland, California, develops and manufactures advanced bioprinting technologies to create lab-grown human tissues. Established in 2018, the company offers the FLUX-1, a 3D bioprinter that integrates conventional bioprinting methods with electro-hydrodynamic printing capabilities. This technology enables the production of complex tissues, such as skin, cartilage, and bone, while also facilitating drug toxicity testing, tissue implants, drug screening, and disease modeling. Frontier Bio aims to replace animal studies with ethically developed human tissues, ultimately working towards eliminating the organ transplant waitlist and improving patient outcomes. The company focuses on achieving complete cell survivability during the printing process, ensuring the viability of the printed tissues for various medical applications.